- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06391814
Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)
Open-Label Individual Patient Study of Epstein-Barr Virus (EBV) Specific T-Cell Lines for the Treatment of a Lymphoproliferative Disease and Hemophagocytic Syndrome Associated With EBV
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Following a presumed primary EBV infection, a 19 year old female patient rapidly suffered systemic inflammatory response, hemophagocytosis, multi-organ failure and evidence of EBV+ T-cell lymphoma.
The patient was aggressively treated and responded to SMILE-based chemotherapy. Once complete response was ascertained by PET imaging, the patient underwent myeloablative HLA-matched unrelated allogeneic stem cell transplantation (cyclophosphamide 60mg/Kg, total body irradiation - 12Gy with anti-thymocyte globulin). The stem cell donor had a positive serology for EBV (IgG).
The patient's EBV titer was weakly positive at the time of transplantation. A decision was made to offer consolidative treatment consisting of donor-derived ex vivo expanded EBV-reactive T cells following transplantation.
A EBV-specific T-cell line was manufactured from a portion of the cryopreserved G-CSF mobilized peripheral graft after appropriate authorizations were obtained.
The patient suffered a severe episode of intestinal graft-versus-host disease early following transplantation but received a first dose of EBV-reactive T cells (20x10e6 T cells/meter square of body surface area 5 months post-transplantation
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jean-Sébastien Delisle, MD, PhD
- Phone Number: 6381 514-252-3400
- Email: js.delisle@umontreal.ca
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H1T 2M4
- Recruiting
- Ciusss-Emtl
-
Contact:
- Jean-Sébastien Delisle, MD, PhD
- Phone Number: 6381 514-252-3400
- Email: js.delisle@umontreal.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Capacity to provide informed consent
- Age ≥ 18
- Negative serum pregnancy test and use of effective contraception method.
Exclusion Criteria:
- Administration within less than 28 days of T-cell depleting antibodies (ATG, OKT3, Campath)
- Pregnancy
- Any abnormal condition or laboratory result that is considered by the Principal Investigator capable of altering patient or study outcome.
- Active uncontrolled GVHD (acute GVHD grade II-IV or progressive extensive chronic GVHD) at time of enrolment or infusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of a donor-derived EBV-specific T-cell line as assessed clinically by the lack of graft-versus-host host (GVHD).
Time Frame: 1 year
|
Evaluate the safety in terms of occurrence of graft-versus-host disease of a donor-derived allogeneic EBV-specific T-cell line generation and infusion in a patient suffering from a life-threatening EBV-related disease who received an allogeneic stem cell transplantation.
Acute GVHD symptoms will be scored using MAGIC criteria using scores from 0 to IV, IV being the most severe involvement) on skin, liver and gastro-intestinal tract.
Chronic GVHD symptoms will be score using the NIH consensus scale (0 to 3, 3 being the most severe) on the following organs skin, mouth, eyes, GI tract, liver, lungs, joints and fascia, and genital tract.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical response
Time Frame: 1 year
|
Disease recurrence as assessed by imaging (PET scanning)
|
1 year
|
Immune reconstitution to EBV
Time Frame: 1 year
|
Measurement of viral titers (nucleic acid testing) and peripheral blood ELISpot measurements
|
1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024-3579
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on EBV Associated Lymphoma
-
Viracta Therapeutics, Inc.RecruitingEBV Related Non-Hodgkin's Lymphoma | Epstein-Barr Virus Associated Lymphoproliferative Disorder | EBV-Related PTLD | EBV Associated Lymphoma | EBV-Positive DLBCL, NOS | EBV Related PTCL, NOSUnited States, Spain, Italy, United Kingdom, Singapore, Taiwan, Korea, Republic of, Germany, Canada, Brazil, Australia, France, Malaysia, Hong Kong, Israel
-
Nantes University HospitalUnknown
-
Memorial Sloan Kettering Cancer CenterWithdrawnEBV Lymphomas | EBV-associated Malignancies
-
Atara BiotherapeuticsNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer CenterCompletedEBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV LymphomaUnited States
-
EutilexRecruitingEBV Associated Extranodal NK/T-cell Lymphoma | EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinomaKorea, Republic of
-
Baylor College of MedicineThe Methodist Hospital Research InstituteRecruitingEBV-Related Hodgkin Lymphoma | EBV Related Non-Hodgkin's Lymphoma | EBV-Related Lymphoproliferative DisorderUnited States
-
Kousai Bio Co., Ltd.Kousai Bio Co., Ltd.Active, not recruitingEBV-associated LymphomasChina
-
Atara BiotherapeuticsMemorial Sloan Kettering Cancer CenterCompletedEBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV LymphomaUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedLymphoproliferative Disorders | Hodgkin Lymphoma | EBV Related Non-Hodgkin's Lymphoma | NonHodgkin Lymphoma | EBV-Related PTLD | EBV Related Lymphoma | EBV Related Hodgkin's LymphomaUnited States
-
Atara BiotherapeuticsNo longer availableLymphoproliferative Disorders | Stem Cell Transplant Complications | Epstein-Barr Virus (EBV) Infections | EBV+ Associated Lymphoma | EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Epstein-Barr Viremia | Lymphoma, AIDS-related | Epstein-Barr Virus-associated Lymphoproliferative... and other conditions
Clinical Trials on EBV-specific T cells
-
Memorial Sloan Kettering Cancer CenterWithdrawnEBV Lymphomas | EBV-associated Malignancies
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedEpstein-Barr Virus InfectionsUnited States
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina
-
Baylor College of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); The Methodist... and other collaboratorsRecruitingLymphoma | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Lymphoproliferative DiseaseUnited States
-
Catherine BollardM.D. Anderson Cancer CenterRecruitingViral InfectionUnited States
-
Prof. Tobias FeuchtingerEuropean Commission; Simbec-Orion Group Ltd, Merthyr Tydfil, UK; Miltenyi Biotec... and other collaboratorsRecruitingCMV Infection | EBV Infection | Stem Cell Transplant Complications | AdV InfectionBelgium, Spain, France, Germany, Italy, Netherlands
-
Beijing Friendship HospitalRecruitingChronic Active Epstein-Barr Virus Infection | Virus-Associated Hemophagocytic SyndromeChina
-
Atara BiotherapeuticsMemorial Sloan Kettering Cancer CenterCompletedEBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV LymphomaUnited States
-
University of Erlangen-Nürnberg Medical SchoolGerman Research Foundation; Charite University, Berlin, Germany; Ludwig-Maximilians... and other collaboratorsCompletedPatients Undergoing Allogeneic Stem Cell TransplantationGermany
-
Chinese PLA General HospitalRecruitingEBV Infection After Allogenic HSCTChina